nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—ALB—hematologic cancer	0.157	1	CbGaD
Repaglinide—SLCO1B1—Irinotecan—hematologic cancer	0.0336	0.0711	CbGbCtD
Repaglinide—CYP2C8—Bortezomib—hematologic cancer	0.0311	0.0657	CbGbCtD
Repaglinide—ALB—Imatinib—hematologic cancer	0.0295	0.0623	CbGbCtD
Repaglinide—CYP2C8—Ifosfamide—hematologic cancer	0.0238	0.0504	CbGbCtD
Repaglinide—CYP2C8—Nilotinib—hematologic cancer	0.0207	0.0438	CbGbCtD
Repaglinide—CYP3A4—Bexarotene—hematologic cancer	0.0206	0.0435	CbGbCtD
Repaglinide—ALB—Prednisone—hematologic cancer	0.0194	0.0411	CbGbCtD
Repaglinide—CYP3A4—Lomustine—hematologic cancer	0.0191	0.0404	CbGbCtD
Repaglinide—CYP3A4—Busulfan—hematologic cancer	0.0191	0.0404	CbGbCtD
Repaglinide—ALB—Irinotecan—hematologic cancer	0.0184	0.0389	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—hematologic cancer	0.0178	0.0376	CbGbCtD
Repaglinide—CYP3A4—Thiotepa—hematologic cancer	0.017	0.036	CbGbCtD
Repaglinide—CYP3A4—Methoxsalen—hematologic cancer	0.0132	0.028	CbGbCtD
Repaglinide—CYP3A4—Bortezomib—hematologic cancer	0.0126	0.0267	CbGbCtD
Repaglinide—CYP3A4—Daunorubicin—hematologic cancer	0.0121	0.0255	CbGbCtD
Repaglinide—CYP2C8—Etoposide—hematologic cancer	0.0114	0.0241	CbGbCtD
Repaglinide—CYP3A4—Cytarabine—hematologic cancer	0.0106	0.0225	CbGbCtD
Repaglinide—CYP3A4—Teniposide—hematologic cancer	0.0105	0.0222	CbGbCtD
Repaglinide—ALB—Methotrexate—hematologic cancer	0.00974	0.0206	CbGbCtD
Repaglinide—CYP3A4—Ifosfamide—hematologic cancer	0.00966	0.0204	CbGbCtD
Repaglinide—CYP2C8—Dexamethasone—hematologic cancer	0.00936	0.0198	CbGbCtD
Repaglinide—CYP3A4—Imatinib—hematologic cancer	0.00923	0.0195	CbGbCtD
Repaglinide—CYP3A4—Ruxolitinib—hematologic cancer	0.00869	0.0184	CbGbCtD
Repaglinide—CYP3A4—Nilotinib—hematologic cancer	0.00839	0.0177	CbGbCtD
Repaglinide—CYP3A4—Vinorelbine—hematologic cancer	0.00832	0.0176	CbGbCtD
Repaglinide—CYP3A4—Triamcinolone—hematologic cancer	0.00761	0.0161	CbGbCtD
Repaglinide—CYP3A4—Dasatinib—hematologic cancer	0.00741	0.0157	CbGbCtD
Repaglinide—CYP3A4—Mitoxantrone—hematologic cancer	0.00732	0.0155	CbGbCtD
Repaglinide—CYP3A4—Betamethasone—hematologic cancer	0.00653	0.0138	CbGbCtD
Repaglinide—CYP3A4—Prednisolone—hematologic cancer	0.00644	0.0136	CbGbCtD
Repaglinide—CYP3A4—Prednisone—hematologic cancer	0.00608	0.0129	CbGbCtD
Repaglinide—CYP3A4—Irinotecan—hematologic cancer	0.00577	0.0122	CbGbCtD
Repaglinide—CYP3A4—Vinblastine—hematologic cancer	0.00513	0.0108	CbGbCtD
Repaglinide—CYP3A4—Vincristine—hematologic cancer	0.00504	0.0107	CbGbCtD
Repaglinide—CYP3A4—Etoposide—hematologic cancer	0.00462	0.00977	CbGbCtD
Repaglinide—CYP3A4—Dexamethasone—hematologic cancer	0.0038	0.00803	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—hematologic cancer	0.00315	0.00666	CbGbCtD
Repaglinide—PPARG—Ponatinib—Nilotinib—hematologic cancer	0.00137	0.285	CbGdCrCtD
Repaglinide—KCNJ11—hematopoietic system—hematologic cancer	0.0011	0.123	CbGeAlD
Repaglinide—PPARG—Ponatinib—Imatinib—hematologic cancer	0.00104	0.216	CbGdCrCtD
Repaglinide—PPARG—Topotecan—Irinotecan—hematologic cancer	0.000987	0.204	CbGdCrCtD
Repaglinide—PPARG—Etoposide—Teniposide—hematologic cancer	0.000981	0.203	CbGdCrCtD
Repaglinide—SLCO1B1—hematopoietic system—hematologic cancer	0.0009	0.1	CbGeAlD
Repaglinide—PPARG—hematopoietic system—hematologic cancer	0.000776	0.0866	CbGeAlD
Repaglinide—SLCO1B1—blood—hematologic cancer	0.000596	0.0665	CbGeAlD
Repaglinide—ABCC8—testis—hematologic cancer	0.000557	0.0622	CbGeAlD
Repaglinide—PPARG—blood—hematologic cancer	0.000514	0.0574	CbGeAlD
Repaglinide—CYP2C8—hematopoietic system—hematologic cancer	0.000512	0.0571	CbGeAlD
Repaglinide—PPARG—bone marrow—hematologic cancer	0.000498	0.0555	CbGeAlD
Repaglinide—PPARG—lung—hematologic cancer	0.000451	0.0503	CbGeAlD
Repaglinide—PPARG—Teniposide—Etoposide—hematologic cancer	0.000445	0.0921	CbGdCrCtD
Repaglinide—KCNJ11—lymph node—hematologic cancer	0.000439	0.0489	CbGeAlD
Repaglinide—PPARG—testis—hematologic cancer	0.000425	0.0475	CbGeAlD
Repaglinide—ALB—testis—hematologic cancer	0.000399	0.0445	CbGeAlD
Repaglinide—CYP3A4—hematopoietic system—hematologic cancer	0.000347	0.0387	CbGeAlD
Repaglinide—CYP2C8—blood—hematologic cancer	0.000339	0.0378	CbGeAlD
Repaglinide—PPARG—lymph node—hematologic cancer	0.000308	0.0344	CbGeAlD
Repaglinide—ALB—lymph node—hematologic cancer	0.000289	0.0323	CbGeAlD
Repaglinide—CYP2C8—testis—hematologic cancer	0.00028	0.0313	CbGeAlD
Repaglinide—CYP3A4—blood—hematologic cancer	0.00023	0.0256	CbGeAlD
Repaglinide—Dermatitis—Thalidomide—hematologic cancer	7.54e-05	0.000294	CcSEcCtD
Repaglinide—Diarrhoea—Vincristine—hematologic cancer	7.51e-05	0.000293	CcSEcCtD
Repaglinide—Headache—Thalidomide—hematologic cancer	7.5e-05	0.000292	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—hematologic cancer	7.49e-05	0.000292	CcSEcCtD
Repaglinide—Hepatobiliary disease—Epirubicin—hematologic cancer	7.39e-05	0.000288	CcSEcCtD
Repaglinide—Pruritus—Gemcitabine—hematologic cancer	7.36e-05	0.000287	CcSEcCtD
Repaglinide—Nausea—Thiotepa—hematologic cancer	7.35e-05	0.000286	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	7.34e-05	0.000286	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—hematologic cancer	7.33e-05	0.000286	CcSEcCtD
Repaglinide—Anaphylactic shock—Betamethasone—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Oedema—Betamethasone—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Oedema—Dexamethasone—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Anaphylactic shock—Dexamethasone—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Diarrhoea—Mitoxantrone—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Diarrhoea—Irinotecan—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Vomiting—Carmustine—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Repaglinide—Gastrointestinal pain—Etoposide—hematologic cancer	7.27e-05	0.000283	CcSEcCtD
Repaglinide—Rash—Carmustine—hematologic cancer	7.25e-05	0.000282	CcSEcCtD
Repaglinide—Dermatitis—Carmustine—hematologic cancer	7.24e-05	0.000282	CcSEcCtD
Repaglinide—Vomiting—Alitretinoin—hematologic cancer	7.24e-05	0.000282	CcSEcCtD
Repaglinide—Paraesthesia—Triamcinolone—hematologic cancer	7.24e-05	0.000282	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—hematologic cancer	7.22e-05	0.000281	CcSEcCtD
Repaglinide—Headache—Carmustine—hematologic cancer	7.2e-05	0.000281	CcSEcCtD
Repaglinide—Rash—Alitretinoin—hematologic cancer	7.18e-05	0.00028	CcSEcCtD
Repaglinide—Dermatitis—Alitretinoin—hematologic cancer	7.17e-05	0.000279	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	7.16e-05	0.000279	CcSEcCtD
Repaglinide—Thrombocytopenia—Dexamethasone—hematologic cancer	7.16e-05	0.000279	CcSEcCtD
Repaglinide—Thrombocytopenia—Betamethasone—hematologic cancer	7.16e-05	0.000279	CcSEcCtD
Repaglinide—Vomiting—Ifosfamide—hematologic cancer	7.15e-05	0.000279	CcSEcCtD
Repaglinide—Hypersensitivity—Cisplatin—hematologic cancer	7.15e-05	0.000279	CcSEcCtD
Repaglinide—Headache—Alitretinoin—hematologic cancer	7.13e-05	0.000278	CcSEcCtD
Repaglinide—Diarrhoea—Gemcitabine—hematologic cancer	7.12e-05	0.000278	CcSEcCtD
Repaglinide—Nausea—Thalidomide—hematologic cancer	7.11e-05	0.000277	CcSEcCtD
Repaglinide—Dyspepsia—Triamcinolone—hematologic cancer	7.1e-05	0.000277	CcSEcCtD
Repaglinide—Rash—Ifosfamide—hematologic cancer	7.09e-05	0.000276	CcSEcCtD
Repaglinide—Dermatitis—Ifosfamide—hematologic cancer	7.09e-05	0.000276	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—hematologic cancer	7.08e-05	0.000276	CcSEcCtD
Repaglinide—Urticaria—Etoposide—hematologic cancer	7.06e-05	0.000275	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—hematologic cancer	7.04e-05	0.000275	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—hematologic cancer	7.03e-05	0.000274	CcSEcCtD
Repaglinide—Abdominal pain—Etoposide—hematologic cancer	7.02e-05	0.000274	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—hematologic cancer	7.02e-05	0.000274	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—hematologic cancer	7.01e-05	0.000273	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—hematologic cancer	7e-05	0.000273	CcSEcCtD
Repaglinide—Vomiting—Vincristine—hematologic cancer	6.97e-05	0.000272	CcSEcCtD
Repaglinide—Urticaria—Prednisolone—hematologic cancer	6.96e-05	0.000271	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—hematologic cancer	6.95e-05	0.000271	CcSEcCtD
Repaglinide—Rash—Vincristine—hematologic cancer	6.92e-05	0.00027	CcSEcCtD
Repaglinide—Dermatitis—Vincristine—hematologic cancer	6.91e-05	0.000269	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—hematologic cancer	6.91e-05	0.000269	CcSEcCtD
Repaglinide—Headache—Vincristine—hematologic cancer	6.87e-05	0.000268	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.83e-05	0.000266	CcSEcCtD
Repaglinide—Nausea—Carmustine—hematologic cancer	6.83e-05	0.000266	CcSEcCtD
Repaglinide—Vomiting—Mitoxantrone—hematologic cancer	6.79e-05	0.000265	CcSEcCtD
Repaglinide—Vomiting—Irinotecan—hematologic cancer	6.79e-05	0.000265	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—hematologic cancer	6.78e-05	0.000264	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—hematologic cancer	6.77e-05	0.000264	CcSEcCtD
Repaglinide—Nausea—Alitretinoin—hematologic cancer	6.76e-05	0.000264	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—hematologic cancer	6.76e-05	0.000263	CcSEcCtD
Repaglinide—Hypertension—Prednisone—hematologic cancer	6.74e-05	0.000263	CcSEcCtD
Repaglinide—Rash—Mitoxantrone—hematologic cancer	6.74e-05	0.000263	CcSEcCtD
Repaglinide—Rash—Irinotecan—hematologic cancer	6.74e-05	0.000263	CcSEcCtD
Repaglinide—Dermatitis—Mitoxantrone—hematologic cancer	6.73e-05	0.000262	CcSEcCtD
Repaglinide—Dermatitis—Irinotecan—hematologic cancer	6.73e-05	0.000262	CcSEcCtD
Repaglinide—Headache—Mitoxantrone—hematologic cancer	6.69e-05	0.000261	CcSEcCtD
Repaglinide—Headache—Irinotecan—hematologic cancer	6.69e-05	0.000261	CcSEcCtD
Repaglinide—Nausea—Ifosfamide—hematologic cancer	6.68e-05	0.00026	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.66e-05	0.00026	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.66e-05	0.00026	CcSEcCtD
Repaglinide—Arthralgia—Prednisone—hematologic cancer	6.64e-05	0.000259	CcSEcCtD
Repaglinide—Diarrhoea—Cisplatin—hematologic cancer	6.64e-05	0.000259	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—hematologic cancer	6.63e-05	0.000258	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—hematologic cancer	6.62e-05	0.000258	CcSEcCtD
Repaglinide—Vomiting—Gemcitabine—hematologic cancer	6.62e-05	0.000258	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.6e-05	0.000257	CcSEcCtD
Repaglinide—Paraesthesia—Dexamethasone—hematologic cancer	6.57e-05	0.000256	CcSEcCtD
Repaglinide—Paraesthesia—Betamethasone—hematologic cancer	6.57e-05	0.000256	CcSEcCtD
Repaglinide—Rash—Gemcitabine—hematologic cancer	6.56e-05	0.000256	CcSEcCtD
Repaglinide—Dermatitis—Gemcitabine—hematologic cancer	6.56e-05	0.000255	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—hematologic cancer	6.55e-05	0.000255	CcSEcCtD
Repaglinide—Hypersensitivity—Etoposide—hematologic cancer	6.55e-05	0.000255	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—hematologic cancer	6.52e-05	0.000254	CcSEcCtD
Repaglinide—Erythema—Methotrexate—hematologic cancer	6.52e-05	0.000254	CcSEcCtD
Repaglinide—Headache—Gemcitabine—hematologic cancer	6.52e-05	0.000254	CcSEcCtD
Repaglinide—Nausea—Vincristine—hematologic cancer	6.52e-05	0.000254	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—hematologic cancer	6.51e-05	0.000254	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—hematologic cancer	6.5e-05	0.000253	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—hematologic cancer	6.49e-05	0.000253	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisolone—hematologic cancer	6.46e-05	0.000252	CcSEcCtD
Repaglinide—Dyspepsia—Dexamethasone—hematologic cancer	6.44e-05	0.000251	CcSEcCtD
Repaglinide—Dyspepsia—Betamethasone—hematologic cancer	6.44e-05	0.000251	CcSEcCtD
Repaglinide—Urticaria—Triamcinolone—hematologic cancer	6.4e-05	0.00025	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—hematologic cancer	6.39e-05	0.000249	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisone—hematologic cancer	6.37e-05	0.000248	CcSEcCtD
Repaglinide—Oedema—Prednisone—hematologic cancer	6.37e-05	0.000248	CcSEcCtD
Repaglinide—Nausea—Irinotecan—hematologic cancer	6.35e-05	0.000247	CcSEcCtD
Repaglinide—Nausea—Mitoxantrone—hematologic cancer	6.35e-05	0.000247	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—hematologic cancer	6.33e-05	0.000247	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.31e-05	0.000246	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.31e-05	0.000246	CcSEcCtD
Repaglinide—Back pain—Methotrexate—hematologic cancer	6.31e-05	0.000246	CcSEcCtD
Repaglinide—Pruritus—Etoposide—hematologic cancer	6.29e-05	0.000245	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—hematologic cancer	6.26e-05	0.000244	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—hematologic cancer	6.25e-05	0.000244	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—hematologic cancer	6.2e-05	0.000241	CcSEcCtD
Repaglinide—Skin disorder—Prednisone—hematologic cancer	6.19e-05	0.000241	CcSEcCtD
Repaglinide—Nausea—Gemcitabine—hematologic cancer	6.18e-05	0.000241	CcSEcCtD
Repaglinide—Vomiting—Cisplatin—hematologic cancer	6.17e-05	0.00024	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—hematologic cancer	6.13e-05	0.000239	CcSEcCtD
Repaglinide—Rash—Cisplatin—hematologic cancer	6.12e-05	0.000238	CcSEcCtD
Repaglinide—Dermatitis—Cisplatin—hematologic cancer	6.11e-05	0.000238	CcSEcCtD
Repaglinide—Erythema—Epirubicin—hematologic cancer	6.1e-05	0.000238	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—hematologic cancer	6.1e-05	0.000238	CcSEcCtD
Repaglinide—Diarrhoea—Etoposide—hematologic cancer	6.08e-05	0.000237	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—hematologic cancer	6.06e-05	0.000236	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—hematologic cancer	6.02e-05	0.000235	CcSEcCtD
Repaglinide—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.98e-05	0.000233	CcSEcCtD
Repaglinide—Gastrointestinal pain—Betamethasone—hematologic cancer	5.98e-05	0.000233	CcSEcCtD
Repaglinide—Hypersensitivity—Triamcinolone—hematologic cancer	5.94e-05	0.000231	CcSEcCtD
Repaglinide—Back pain—Epirubicin—hematologic cancer	5.9e-05	0.00023	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—hematologic cancer	5.86e-05	0.000228	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—hematologic cancer	5.84e-05	0.000228	CcSEcCtD
Repaglinide—Urticaria—Dexamethasone—hematologic cancer	5.81e-05	0.000226	CcSEcCtD
Repaglinide—Urticaria—Betamethasone—hematologic cancer	5.81e-05	0.000226	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.8e-05	0.000226	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—hematologic cancer	5.8e-05	0.000226	CcSEcCtD
Repaglinide—Abdominal pain—Betamethasone—hematologic cancer	5.78e-05	0.000225	CcSEcCtD
Repaglinide—Abdominal pain—Dexamethasone—hematologic cancer	5.78e-05	0.000225	CcSEcCtD
Repaglinide—Nausea—Cisplatin—hematologic cancer	5.76e-05	0.000225	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—hematologic cancer	5.73e-05	0.000223	CcSEcCtD
Repaglinide—Paraesthesia—Prednisone—hematologic cancer	5.72e-05	0.000223	CcSEcCtD
Repaglinide—Pruritus—Triamcinolone—hematologic cancer	5.7e-05	0.000222	CcSEcCtD
Repaglinide—Vomiting—Etoposide—hematologic cancer	5.65e-05	0.00022	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—hematologic cancer	5.65e-05	0.00022	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—hematologic cancer	5.65e-05	0.00022	CcSEcCtD
Repaglinide—Dyspepsia—Prednisone—hematologic cancer	5.61e-05	0.000219	CcSEcCtD
Repaglinide—Rash—Etoposide—hematologic cancer	5.6e-05	0.000218	CcSEcCtD
Repaglinide—Dermatitis—Etoposide—hematologic cancer	5.6e-05	0.000218	CcSEcCtD
Repaglinide—Headache—Etoposide—hematologic cancer	5.57e-05	0.000217	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—hematologic cancer	5.55e-05	0.000216	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—hematologic cancer	5.55e-05	0.000216	CcSEcCtD
Repaglinide—Rash—Prednisolone—hematologic cancer	5.53e-05	0.000215	CcSEcCtD
Repaglinide—Dermatitis—Prednisolone—hematologic cancer	5.52e-05	0.000215	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.51e-05	0.000215	CcSEcCtD
Repaglinide—Headache—Prednisolone—hematologic cancer	5.49e-05	0.000214	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—hematologic cancer	5.46e-05	0.000213	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—hematologic cancer	5.46e-05	0.000213	CcSEcCtD
Repaglinide—Constipation—Prednisone—hematologic cancer	5.45e-05	0.000212	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—hematologic cancer	5.39e-05	0.00021	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—hematologic cancer	5.32e-05	0.000207	CcSEcCtD
Repaglinide—Nausea—Etoposide—hematologic cancer	5.28e-05	0.000206	CcSEcCtD
Repaglinide—Hypertension—Epirubicin—hematologic cancer	5.27e-05	0.000205	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—hematologic cancer	5.21e-05	0.000203	CcSEcCtD
Repaglinide—Gastrointestinal pain—Prednisone—hematologic cancer	5.21e-05	0.000203	CcSEcCtD
Repaglinide—Nausea—Prednisolone—hematologic cancer	5.21e-05	0.000203	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—hematologic cancer	5.2e-05	0.000203	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—hematologic cancer	5.2e-05	0.000203	CcSEcCtD
Repaglinide—Pruritus—Dexamethasone—hematologic cancer	5.17e-05	0.000202	CcSEcCtD
Repaglinide—Pruritus—Betamethasone—hematologic cancer	5.17e-05	0.000202	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—hematologic cancer	5.17e-05	0.000202	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.16e-05	0.000201	CcSEcCtD
Repaglinide—Vomiting—Triamcinolone—hematologic cancer	5.12e-05	0.0002	CcSEcCtD
Repaglinide—Rash—Triamcinolone—hematologic cancer	5.08e-05	0.000198	CcSEcCtD
Repaglinide—Dermatitis—Triamcinolone—hematologic cancer	5.08e-05	0.000198	CcSEcCtD
Repaglinide—Urticaria—Prednisone—hematologic cancer	5.06e-05	0.000197	CcSEcCtD
Repaglinide—Leukopenia—Doxorubicin—hematologic cancer	5.06e-05	0.000197	CcSEcCtD
Repaglinide—Headache—Triamcinolone—hematologic cancer	5.05e-05	0.000197	CcSEcCtD
Repaglinide—Abdominal pain—Prednisone—hematologic cancer	5.03e-05	0.000196	CcSEcCtD
Repaglinide—Diarrhoea—Betamethasone—hematologic cancer	5e-05	0.000195	CcSEcCtD
Repaglinide—Diarrhoea—Dexamethasone—hematologic cancer	5e-05	0.000195	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—hematologic cancer	4.99e-05	0.000195	CcSEcCtD
Repaglinide—Oedema—Epirubicin—hematologic cancer	4.98e-05	0.000194	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—hematologic cancer	4.98e-05	0.000194	CcSEcCtD
Repaglinide—Thrombocytopenia—Epirubicin—hematologic cancer	4.88e-05	0.00019	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—hematologic cancer	4.88e-05	0.00019	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.85e-05	0.000189	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—hematologic cancer	4.84e-05	0.000189	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—hematologic cancer	4.81e-05	0.000187	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—hematologic cancer	4.81e-05	0.000187	CcSEcCtD
Repaglinide—Nausea—Triamcinolone—hematologic cancer	4.79e-05	0.000187	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—hematologic cancer	4.78e-05	0.000186	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.77e-05	0.000186	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisone—hematologic cancer	4.69e-05	0.000183	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—hematologic cancer	4.69e-05	0.000183	CcSEcCtD
Repaglinide—Vomiting—Betamethasone—hematologic cancer	4.65e-05	0.000181	CcSEcCtD
Repaglinide—Vomiting—Dexamethasone—hematologic cancer	4.65e-05	0.000181	CcSEcCtD
Repaglinide—Rash—Dexamethasone—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Rash—Betamethasone—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Anaphylactic shock—Doxorubicin—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Dermatitis—Dexamethasone—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Dermatitis—Betamethasone—hematologic cancer	4.61e-05	0.00018	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.6e-05	0.000179	CcSEcCtD
Repaglinide—Headache—Betamethasone—hematologic cancer	4.58e-05	0.000179	CcSEcCtD
Repaglinide—Headache—Dexamethasone—hematologic cancer	4.58e-05	0.000179	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.54e-05	0.000177	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—hematologic cancer	4.51e-05	0.000176	CcSEcCtD
Repaglinide—Pruritus—Prednisone—hematologic cancer	4.51e-05	0.000176	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—hematologic cancer	4.48e-05	0.000174	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—hematologic cancer	4.47e-05	0.000174	CcSEcCtD
Repaglinide—Dyspepsia—Epirubicin—hematologic cancer	4.38e-05	0.000171	CcSEcCtD
Repaglinide—Diarrhoea—Prednisone—hematologic cancer	4.36e-05	0.00017	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—hematologic cancer	4.35e-05	0.00017	CcSEcCtD
Repaglinide—Nausea—Betamethasone—hematologic cancer	4.34e-05	0.000169	CcSEcCtD
Repaglinide—Nausea—Dexamethasone—hematologic cancer	4.34e-05	0.000169	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.3e-05	0.000168	CcSEcCtD
Repaglinide—Constipation—Epirubicin—hematologic cancer	4.26e-05	0.000166	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—hematologic cancer	4.23e-05	0.000165	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—hematologic cancer	4.21e-05	0.000164	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.2e-05	0.000164	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—hematologic cancer	4.14e-05	0.000161	CcSEcCtD
Repaglinide—Gastrointestinal pain—Epirubicin—hematologic cancer	4.07e-05	0.000159	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—hematologic cancer	4.06e-05	0.000158	CcSEcCtD
Repaglinide—Vomiting—Prednisone—hematologic cancer	4.05e-05	0.000158	CcSEcCtD
Repaglinide—Rash—Prednisone—hematologic cancer	4.02e-05	0.000157	CcSEcCtD
Repaglinide—Dermatitis—Prednisone—hematologic cancer	4.01e-05	0.000156	CcSEcCtD
Repaglinide—Headache—Prednisone—hematologic cancer	3.99e-05	0.000156	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.98e-05	0.000155	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—hematologic cancer	3.96e-05	0.000154	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—hematologic cancer	3.94e-05	0.000154	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—hematologic cancer	3.94e-05	0.000153	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—hematologic cancer	3.92e-05	0.000153	CcSEcCtD
Repaglinide—Nausea—Prednisone—hematologic cancer	3.78e-05	0.000147	CcSEcCtD
Repaglinide—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.77e-05	0.000147	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—hematologic cancer	3.77e-05	0.000147	CcSEcCtD
Repaglinide—Hypersensitivity—Epirubicin—hematologic cancer	3.67e-05	0.000143	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—hematologic cancer	3.66e-05	0.000143	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—hematologic cancer	3.64e-05	0.000142	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—hematologic cancer	3.64e-05	0.000142	CcSEcCtD
Repaglinide—Pruritus—Epirubicin—hematologic cancer	3.52e-05	0.000137	CcSEcCtD
Repaglinide—Diarrhoea—Epirubicin—hematologic cancer	3.41e-05	0.000133	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—hematologic cancer	3.4e-05	0.000132	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—hematologic cancer	3.38e-05	0.000132	CcSEcCtD
Repaglinide—Rash—Methotrexate—hematologic cancer	3.36e-05	0.000131	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—hematologic cancer	3.35e-05	0.000131	CcSEcCtD
Repaglinide—Headache—Methotrexate—hematologic cancer	3.33e-05	0.00013	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—hematologic cancer	3.26e-05	0.000127	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—hematologic cancer	3.17e-05	0.000123	CcSEcCtD
Repaglinide—Nausea—Methotrexate—hematologic cancer	3.16e-05	0.000123	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—hematologic cancer	3.15e-05	0.000123	CcSEcCtD
Repaglinide—Rash—Epirubicin—hematologic cancer	3.14e-05	0.000122	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—hematologic cancer	3.14e-05	0.000122	CcSEcCtD
Repaglinide—Headache—Epirubicin—hematologic cancer	3.12e-05	0.000122	CcSEcCtD
Repaglinide—Nausea—Epirubicin—hematologic cancer	2.96e-05	0.000115	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—hematologic cancer	2.93e-05	0.000114	CcSEcCtD
Repaglinide—Rash—Doxorubicin—hematologic cancer	2.91e-05	0.000113	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—hematologic cancer	2.9e-05	0.000113	CcSEcCtD
Repaglinide—Headache—Doxorubicin—hematologic cancer	2.89e-05	0.000113	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—hematologic cancer	2.74e-05	0.000107	CcSEcCtD
Repaglinide—CYP2C8—Metabolism—ARNTL—hematologic cancer	1.34e-05	0.000134	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.33e-05	0.000134	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—ESR1—hematologic cancer	1.33e-05	0.000134	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ARNTL—hematologic cancer	1.33e-05	0.000134	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.33e-05	0.000133	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CG—hematologic cancer	1.33e-05	0.000133	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GSTM1—hematologic cancer	1.32e-05	0.000133	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NCOR1—hematologic cancer	1.32e-05	0.000133	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.31e-05	0.000131	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL2RA—hematologic cancer	1.31e-05	0.000131	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CA9—hematologic cancer	1.3e-05	0.000131	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ACP5—hematologic cancer	1.3e-05	0.000131	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	1.3e-05	0.00013	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CA9—hematologic cancer	1.29e-05	0.00013	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ACP5—hematologic cancer	1.29e-05	0.00013	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—NOTCH1—hematologic cancer	1.29e-05	0.00013	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOR2—hematologic cancer	1.28e-05	0.000129	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYCS—hematologic cancer	1.28e-05	0.000129	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOR2—hematologic cancer	1.28e-05	0.000128	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—HSP90AA1—hematologic cancer	1.28e-05	0.000128	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CREBBP—hematologic cancer	1.27e-05	0.000127	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—TNF—hematologic cancer	1.26e-05	0.000127	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	1.26e-05	0.000127	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PDGFB—hematologic cancer	1.26e-05	0.000127	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—KRAS—hematologic cancer	1.25e-05	0.000126	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—DCK—hematologic cancer	1.25e-05	0.000126	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.25e-05	0.000126	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ASNS—hematologic cancer	1.25e-05	0.000126	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CREBBP—hematologic cancer	1.23e-05	0.000124	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—IDH1—hematologic cancer	1.22e-05	0.000123	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—CDK2—hematologic cancer	1.22e-05	0.000123	CbGpPWpGaD
Repaglinide—ALB—Metabolism—IDH1—hematologic cancer	1.22e-05	0.000122	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TXN—hematologic cancer	1.21e-05	0.000122	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTO1—hematologic cancer	1.21e-05	0.000122	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ABCC3—hematologic cancer	1.21e-05	0.000122	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ABCC3—hematologic cancer	1.2e-05	0.000121	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTO1—hematologic cancer	1.2e-05	0.000121	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TXN—hematologic cancer	1.2e-05	0.000121	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CD—hematologic cancer	1.2e-05	0.000121	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	1.19e-05	0.00012	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—ALB—hematologic cancer	1.19e-05	0.000119	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HDC—hematologic cancer	1.19e-05	0.000119	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SPHK1—hematologic cancer	1.18e-05	0.000119	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SPHK1—hematologic cancer	1.18e-05	0.000118	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—MAPK14—hematologic cancer	1.17e-05	0.000118	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—CREBBP—hematologic cancer	1.17e-05	0.000117	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—MTHFR—hematologic cancer	1.17e-05	0.000117	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CD—hematologic cancer	1.17e-05	0.000117	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	1.16e-05	0.000116	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—ALB—hematologic cancer	1.15e-05	0.000116	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.15e-05	0.000115	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—UGT1A1—hematologic cancer	1.14e-05	0.000114	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—FN1—hematologic cancer	1.14e-05	0.000114	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3R1—hematologic cancer	1.14e-05	0.000114	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTP1—hematologic cancer	1.13e-05	0.000114	CbGpPWpGaD
Repaglinide—ALB—Metabolism—UGT1A1—hematologic cancer	1.13e-05	0.000114	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC22A1—hematologic cancer	1.11e-05	0.000111	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CRABP1—hematologic cancer	1.11e-05	0.000111	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3R1—hematologic cancer	1.1e-05	0.000111	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CRABP1—hematologic cancer	1.1e-05	0.00011	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC22A1—hematologic cancer	1.1e-05	0.00011	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.09e-05	0.00011	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CG—hematologic cancer	1.09e-05	0.000109	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CDA—hematologic cancer	1.08e-05	0.000109	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ALOX5—hematologic cancer	1.08e-05	0.000108	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ALOX5—hematologic cancer	1.07e-05	0.000108	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ABCB1—hematologic cancer	1.07e-05	0.000108	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PTPN11—hematologic cancer	1.07e-05	0.000107	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—HRAS—hematologic cancer	1.07e-05	0.000107	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CB—hematologic cancer	1.05e-05	0.000105	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NUP98—hematologic cancer	1.04e-05	0.000105	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PC—hematologic cancer	1.04e-05	0.000105	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NCOR1—hematologic cancer	1.04e-05	0.000104	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTM1—hematologic cancer	1.04e-05	0.000104	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NUP98—hematologic cancer	1.04e-05	0.000104	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.03e-05	0.000103	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—IL6—hematologic cancer	1.02e-05	0.000102	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CB—hematologic cancer	1.02e-05	0.000102	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA3—hematologic cancer	1.01e-05	0.000102	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ADCY7—hematologic cancer	1.01e-05	0.000102	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—CREBBP—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ADCY7—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA3—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GBA—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NUP214—hematologic cancer	1.01e-05	0.000101	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NUP214—hematologic cancer	1e-05	0.000101	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.96e-06	0.0001	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.91e-06	9.95e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ABCG2—hematologic cancer	9.86e-06	9.9e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTR—hematologic cancer	9.86e-06	9.9e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	9.86e-06	9.9e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTR—hematologic cancer	9.81e-06	9.85e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ABCG2—hematologic cancer	9.81e-06	9.85e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CG—hematologic cancer	9.81e-06	9.85e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ENO2—hematologic cancer	9.67e-06	9.71e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ENO2—hematologic cancer	9.62e-06	9.66e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CD—hematologic cancer	9.57e-06	9.61e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—AKT1—hematologic cancer	9.41e-06	9.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTT1—hematologic cancer	9.38e-06	9.42e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTT1—hematologic cancer	9.33e-06	9.37e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.24e-06	9.28e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTAP—hematologic cancer	9.22e-06	9.26e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—MTHFR—hematologic cancer	9.19e-06	9.23e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.19e-06	9.22e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SDC1—hematologic cancer	9.17e-06	9.21e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SDC1—hematologic cancer	9.12e-06	9.16e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CREBBP—hematologic cancer	9.09e-06	9.13e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTEN—hematologic cancer	9.06e-06	9.1e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3R1—hematologic cancer	9.03e-06	9.07e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTEN—hematologic cancer	8.79e-06	8.82e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—JAK2—hematologic cancer	8.78e-06	8.82e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.76e-06	8.8e-05	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	8.73e-06	8.77e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.71e-06	8.75e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.65e-06	8.68e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—EP300—hematologic cancer	8.64e-06	8.68e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CD—hematologic cancer	8.62e-06	8.66e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ALB—hematologic cancer	8.51e-06	8.55e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—EP300—hematologic cancer	8.38e-06	8.41e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CB—hematologic cancer	8.34e-06	8.37e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.27e-06	8.31e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.22e-06	8.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—FHL2—hematologic cancer	8.22e-06	8.25e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3R1—hematologic cancer	8.14e-06	8.17e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.1e-06	8.13e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AGRN—hematologic cancer	8.06e-06	8.09e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	8.06e-06	8.09e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NQO1—hematologic cancer	7.8e-06	7.83e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CD44—hematologic cancer	7.8e-06	7.83e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CD44—hematologic cancer	7.75e-06	7.79e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NQO1—hematologic cancer	7.75e-06	7.79e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	7.72e-06	7.75e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL2—hematologic cancer	7.66e-06	7.69e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—IDH2—hematologic cancer	7.64e-06	7.67e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HMMR—hematologic cancer	7.64e-06	7.67e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.64e-06	7.67e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.59e-06	7.62e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CB—hematologic cancer	7.51e-06	7.55e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYCS—hematologic cancer	7.38e-06	7.41e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYCS—hematologic cancer	7.34e-06	7.37e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	7.33e-06	7.36e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HSP90AA1—hematologic cancer	7.29e-06	7.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.18e-06	7.21e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CREBBP—hematologic cancer	7.16e-06	7.19e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MAPK3—hematologic cancer	7.14e-06	7.16e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CA9—hematologic cancer	6.99e-06	7.02e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ACP5—hematologic cancer	6.99e-06	7.02e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MYC—hematologic cancer	6.94e-06	6.97e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.9e-06	6.92e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—EP300—hematologic cancer	6.87e-06	6.9e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	6.79e-06	6.82e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ALB—hematologic cancer	6.7e-06	6.73e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SRC—hematologic cancer	6.68e-06	6.71e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.6e-06	6.62e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—IDH1—hematologic cancer	6.57e-06	6.6e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.56e-06	6.59e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—VEGFA—hematologic cancer	6.51e-06	6.54e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTP1—hematologic cancer	6.5e-06	6.53e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TXN—hematologic cancer	6.49e-06	6.52e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.49e-06	6.52e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.49e-06	6.52e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTEN—hematologic cancer	6.49e-06	6.52e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTP1—hematologic cancer	6.47e-06	6.49e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NRAS—hematologic cancer	6.43e-06	6.46e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	6.41e-06	6.44e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CA—hematologic cancer	6.39e-06	6.42e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.36e-06	6.38e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.29e-06	6.32e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.26e-06	6.28e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CA—hematologic cancer	6.2e-06	6.22e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—EP300—hematologic cancer	6.19e-06	6.22e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—MAPK3—hematologic cancer	6.16e-06	6.18e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ABCB1—hematologic cancer	6.16e-06	6.18e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ABCB1—hematologic cancer	6.12e-06	6.15e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.11e-06	6.13e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTM1—hematologic cancer	5.98e-06	6e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOR1—hematologic cancer	5.98e-06	6e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TGFB1—hematologic cancer	5.97e-06	6e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTM1—hematologic cancer	5.94e-06	5.97e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOR1—hematologic cancer	5.94e-06	5.97e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.94e-06	5.96e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.94e-06	5.96e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	5.92e-06	5.94e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.79e-06	5.81e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NUP98—hematologic cancer	5.61e-06	5.63e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—KRAS—hematologic cancer	5.53e-06	5.56e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.44e-06	5.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.44e-06	5.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NUP214—hematologic cancer	5.4e-06	5.43e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTR—hematologic cancer	5.29e-06	5.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.29e-06	5.32e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTHFR—hematologic cancer	5.28e-06	5.3e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTHFR—hematologic cancer	5.25e-06	5.27e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—AKT1—hematologic cancer	5.22e-06	5.24e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ENO2—hematologic cancer	5.19e-06	5.21e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTEN—hematologic cancer	5.11e-06	5.13e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CA—hematologic cancer	5.08e-06	5.1e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—AKT1—hematologic cancer	5.06e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.04e-06	5.06e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SDC1—hematologic cancer	4.92e-06	4.94e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—hematologic cancer	4.92e-06	4.94e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—EP300—hematologic cancer	4.88e-06	4.9e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—AKT1—hematologic cancer	4.81e-06	4.83e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—HRAS—hematologic cancer	4.7e-06	4.72e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.65e-06	4.67e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.63e-06	4.65e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CA—hematologic cancer	4.58e-06	4.6e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CG—hematologic cancer	4.44e-06	4.46e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CG—hematologic cancer	4.41e-06	4.43e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CD44—hematologic cancer	4.19e-06	4.2e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NQO1—hematologic cancer	4.19e-06	4.2e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT1—hematologic cancer	4.15e-06	4.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CREBBP—hematologic cancer	4.11e-06	4.13e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CREBBP—hematologic cancer	4.09e-06	4.11e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYCS—hematologic cancer	3.96e-06	3.98e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.94e-06	3.95e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CD—hematologic cancer	3.9e-06	3.92e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CD—hematologic cancer	3.88e-06	3.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ALB—hematologic cancer	3.85e-06	3.87e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—AKT1—hematologic cancer	3.74e-06	3.76e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3R1—hematologic cancer	3.68e-06	3.7e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3R1—hematologic cancer	3.66e-06	3.68e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	3.61e-06	3.62e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.49e-06	3.51e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CB—hematologic cancer	3.4e-06	3.41e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CB—hematologic cancer	3.38e-06	3.39e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.3e-06	3.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.21e-06	3.22e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.21e-06	3.22e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—AKT1—hematologic cancer	2.95e-06	2.96e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTEN—hematologic cancer	2.94e-06	2.95e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTEN—hematologic cancer	2.92e-06	2.93e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.83e-06	2.85e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—EP300—hematologic cancer	2.8e-06	2.81e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—EP300—hematologic cancer	2.79e-06	2.8e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.38e-06	2.39e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.21e-06	2.22e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.09e-06	2.1e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CA—hematologic cancer	2.07e-06	2.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALB—hematologic cancer	2.07e-06	2.08e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CA—hematologic cancer	2.06e-06	2.07e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.98e-06	1.99e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.83e-06	1.83e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AKT1—hematologic cancer	1.69e-06	1.7e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AKT1—hematologic cancer	1.68e-06	1.69e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTEN—hematologic cancer	1.58e-06	1.58e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—EP300—hematologic cancer	1.5e-06	1.51e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.11e-06	1.12e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AKT1—hematologic cancer	9.09e-07	9.13e-06	CbGpPWpGaD
